MX2022013616A - Anticuerpos anti-dectina-2. - Google Patents

Anticuerpos anti-dectina-2.

Info

Publication number
MX2022013616A
MX2022013616A MX2022013616A MX2022013616A MX2022013616A MX 2022013616 A MX2022013616 A MX 2022013616A MX 2022013616 A MX2022013616 A MX 2022013616A MX 2022013616 A MX2022013616 A MX 2022013616A MX 2022013616 A MX2022013616 A MX 2022013616A
Authority
MX
Mexico
Prior art keywords
methods
binding agents
dectin
inventive
nucleic acids
Prior art date
Application number
MX2022013616A
Other languages
English (en)
Spanish (es)
Inventor
Karla A Henning
David Dornan
Shelley Erin Ackerman
Justin A Kenkel
Original Assignee
Bolt Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bolt Biotherapeutics Inc filed Critical Bolt Biotherapeutics Inc
Publication of MX2022013616A publication Critical patent/MX2022013616A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2022013616A 2020-05-01 2021-05-03 Anticuerpos anti-dectina-2. MX2022013616A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063018952P 2020-05-01 2020-05-01
PCT/US2021/030466 WO2021222894A1 (en) 2020-05-01 2021-05-03 Anti-dectin-2 antibodies

Publications (1)

Publication Number Publication Date
MX2022013616A true MX2022013616A (es) 2022-11-16

Family

ID=76076494

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013616A MX2022013616A (es) 2020-05-01 2021-05-03 Anticuerpos anti-dectina-2.

Country Status (13)

Country Link
US (3) US11753474B2 (cg-RX-API-DMAC7.html)
EP (1) EP4142881A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023524092A (cg-RX-API-DMAC7.html)
KR (1) KR20230005907A (cg-RX-API-DMAC7.html)
CN (1) CN115461122A (cg-RX-API-DMAC7.html)
AU (1) AU2021262828A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022020639A2 (cg-RX-API-DMAC7.html)
CA (1) CA3175576A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003012A1 (cg-RX-API-DMAC7.html)
CR (1) CR20220582A (cg-RX-API-DMAC7.html)
IL (1) IL297782A (cg-RX-API-DMAC7.html)
MX (1) MX2022013616A (cg-RX-API-DMAC7.html)
WO (1) WO2021222894A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12145993B2 (en) * 2016-06-08 2024-11-19 Shanghai Jiao Tong University School Of Medicine Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2024216089A1 (en) * 2023-04-13 2024-10-17 Bolt Biotherapeutics, Inc. Anti-dectin-2 antibody combination therapy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US7071171B1 (en) * 1996-12-20 2006-07-04 Board Of Regents The University Of Texas System Unique dendritic cell-associated c-type lectins, dectin-1 and dectin-2 compositions and uses thereof
AU5345901A (en) 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US20070014795A1 (en) 2004-12-30 2007-01-18 Dhodapkar Madhav V Compositions and methods for enhanced dendritic cell maturation and function
AU2006312148B2 (en) 2005-11-07 2012-04-12 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
HRP20210977T1 (hr) 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
HUE061339T2 (hu) 2014-03-19 2023-06-28 Genzyme Corp Targetáló csoportok helyspecifikus glikotechnikai átalakítása
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Cd73に対する抗体およびその使用
WO2017117269A1 (en) * 2015-12-29 2017-07-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for dectin-2 stimulation and cancer immunotherapy
CN109562153A (zh) 2016-08-07 2019-04-02 诺华股份有限公司 mRNA介导的免疫方法
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
JP2020526482A (ja) * 2017-06-28 2020-08-31 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー デクチン−2刺激及び癌免疫療法のための方法及び組成物
SG11202110663UA (en) 2019-04-05 2021-10-28 Dren Bio Inc Methods of depleting disease causing agents via antibody targeted phagocytosis
EP4225373A4 (en) 2020-10-07 2025-01-08 Dren Bio, Inc. ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
CR20220582A (es) 2023-01-09
BR112022020639A2 (pt) 2022-11-29
CN115461122A (zh) 2022-12-09
EP4142881A1 (en) 2023-03-08
CA3175576A1 (en) 2021-11-04
JP2023524092A (ja) 2023-06-08
US20220153849A1 (en) 2022-05-19
US11753474B2 (en) 2023-09-12
IL297782A (en) 2022-12-01
US12325750B2 (en) 2025-06-10
CL2022003012A1 (es) 2023-06-23
KR20230005907A (ko) 2023-01-10
WO2021222894A1 (en) 2021-11-04
US20230406939A1 (en) 2023-12-21
US20250270329A1 (en) 2025-08-28
AU2021262828A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
CR20220582A (es) Anticuerpos anti-dectina-2
BR112022000371A2 (pt) Anticorpos claudin18 e métodos de tratamento contra câncer
CY1122576T1 (el) Ανθρωπινα αντισωματα που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (leg-3), και χρησεις εξ' αυτων
PH12021551484A1 (en) Antibodies binding to cd3
US20250206793A1 (en) T-cell expansion method and uses
MX2019000149A (es) Proteinas de union a ligando 1 de muerte programada 1 (pd-l1) y metodos de uso de las mismas.
PE20210517A1 (es) Anticuerpos anti-hla-g y utilizacion de los mismos
MX2025012685A (es) Anticuerpos para claudin6 y metodos para tratar el cancer
PH12022500027A1 (en) Antibodies binding to cd3
IL161832A0 (en) Pharmaceutical composition for inducing an immune response in a human or animal
BR112013014265A8 (pt) sequência de ácido nucleico isolada, receptor antígeno quimérico isolado, célula, vetor, e, métodos para estimular uma resposta imune mediada por célula t, para fornecer uma imunidade antitumoral em um mamífero, para tratar um mamífero tendo uma doença, distúrbio ou condição, para tratar um ser humano com uma doença, para gerar uma população persistente de célula t, e para expandir uma população de célula t
PH12021553254A1 (en) Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
MX2022008925A (es) Anticuerpos anti-pd-l1.
PH12022553489A1 (en) Antibodies binding to cd3 and folr1
MX2019012606A (es) Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr.
WO2020185796A9 (en) High avidity wt1 t cell receptors and uses thereof
CR20230025A (es) Muteínas de il-10 y proteínas de fusión de las mismas referencia cruzada a solicitudes relacionadas
WO2023015229A3 (en) Sars-cov-2 virus-like particles
MX2025001237A (es) Celulas modificadas geneticamente con expresion genica reducida para mitigar el reconocimiento de celulas inmunitarias
CL2021000177A1 (es) Péptidos, combinaciones de péptidos, células y kits para el uso en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201802360)
Flaherty et al. H (Tla) system: Identification of two new loci, H-31 and H-32, and alleles
PH12021551903A1 (en) Anti-trem1 antibodies and related methods
AU2019356414A8 (en) Binding proteins specific for HA-1H and uses thereof
WO2002068451A3 (en) Sperm protein 17 for the diagnosis and treatment of cancer
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof